Related Experiment Video

Updated: Jul 18, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Sunitinib malate

Hassane Izzedine1, Irina Buhaescu, Olivier Rixe

  • 1Department of Nephrology, Pitie-Salpetriere Hospital 83, Blvd de l'Hôpital, 75013 Paris, France. hassan.izzedine@psl.ap-hop-paris.fr

Cancer Chemotherapy and Pharmacology
|December 1, 2006
PubMed

Insights

Sunitinib, a multi-targeted tyrosine kinase inhibitor, shows anti-tumor and anti-angiogenic effects. It is approved for advanced renal cell carcinoma and gastrointestinal stromal tumors resistant to imatinib.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Receptor tyrosine kinases (RTKs) like VEGFR, PDGFR, KIT, and FLT3 play key roles in tumor angiogenesis, growth, and metastasis.
  • Understanding RTK roles is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To review pharmacologic and clinical data of sunitinib, a novel multi-targeted tyrosine kinase inhibitor.
  • To highlight sunitinib's efficacy in oncology.

Main Methods:

  • Review of recent pharmacologic and clinical data.
  • Focus on sunitinib's binding affinity for VEGFR and PDGFR.

Main Results:

  • Sunitinib exhibits anti-tumor and anti-angiogenic activities.
  • Sunitinib received FDA approval for advanced renal cell carcinoma (adRCC) and gastrointestinal stromal tumors (GIST) in imatinib-resistant patients.

Conclusions:

  • Sunitinib is a promising oral, multi-targeted tyrosine kinase inhibitor for specific cancer indications.
  • The drug offers a new therapeutic option for patients with advanced RCC and GIST.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...